That is $25 for FDA-approved tirzepatide, compared to $399-524 for Willow compounded version
It lacks the clinical trial data required for FDA clearance
Among them, retatrutide has shown significant clinical advantages in phase II clinical trials, reducing the weight of obese patients by up to 24.2% in 48 weeks and lowering the HbA1c of type 2 diabetes patients by 2.2% in 36 weeks (49, 50)
et al., Altern Ther Health Med (2024) Pilot study on BPC-157 for interstitial cystitis (private clinic) Orthopaedic & Wellness (2023) Peptide Dangers blog highlighting conflicts of interest and unknown risks USADA Spirit of Sport blog (2020): Warning to athletes about BPC-157s unapproved status usada.org
Jenkins ND, Buckner SL, Cochrane KC, Bergstrom HC, Goldsmith JA, Weir JP, et al